<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>26306967</identifier>
<setSpec>1989-2284</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Saurina Sole, Anna</dc:author>
<dc:author>Fulquet Nicolas, Miquel</dc:author>
<dc:author>Pou Potau, Monica</dc:author>
<dc:author>Macias-Toro, Javier</dc:author>
<dc:author>Martínez Calvo, Gemma</dc:author>
<dc:author>Duarte-Gallego, Verónica</dc:author>
<dc:author>Ramírez-de Arellano Serna, Manel</dc:author>
<dc:author>Esteve Simo, Vicent</dc:author>
<dc:author>Moreno-Guzmán, Fátima</dc:author>
<dc:description xml:lang="en">INTRODUCTION Cinacalcet has proved effective to control secondary hyperparathyroidism in patients on haemodialysis (HD). Some studies have reported an appropriate secondary hyperparathyroidism control and a better compliance after intradialytic use of calcimimetics. OBJECTIVES To assess the effect of post-dialysis calcimimetics use on mineral bone disorders and calcimimetics gastrointestinal tolerability in our HD unit. MATERIAL AND METHODS A 12-week single-centre prospective study in HD patients treated with cinacalcet (&gt;2 months). Two study periods: Usual outpatient use (Stage 1) and use after HD session (Stage 2). ENDPOINTS 1) Biochemical MBD data; 2) Gastrointestinal Symptom Rating Scale (GSRS) for gastrointestinal tolerability, and visual analogic scale (VAS) for satisfaction; 3) Adherence: Morisky-Green test (MG) and final tablet count (TC). RESULTS Sixty-two HD patients. Fourteen received cinacalcet (22.5%). TEN patients were included, mean age was 60.9 years; patients had received HD for 80.9 months. Mean Charlson index: 9. Biochemical data: Stage 1 (initial vs. final): Ca 8.8 ± 0.5 vs. 9.1 ± 0.7 mg/dl (p&lt;0.05); P 5.2 ± 0.8 vs. 4.5 ± 1.6 mg/dl, iPTH 360.3 ± 232.7 vs. 349 ± 122 pg/ml. MG: 70%. Stage 2 (initial vs. final): Ca 9.1 ± 0.7 vs. 8.8 ± 0.6 mg/dl; P 4.5 ± 1.6 vs. 4.6 ± 1.3 mg/dl, iPTH 360.3 ± 232.7 vs. 349 ± 122 pg/ml. TC: 89%. GSRS and VAS were better in Stage 2 (GSRS 7.5 ± 5.2 vs. 4.3 ± 1.9; VAS 4.8 ± 2.3 vs. 6.9 ± 2.8). No significant changes were observed in calcimimetic dose (201 vs. 207 mg/wk), number of phosphate binders (9 vs. 8.2 pts/day), native vitamin D (70 vs. 60%), selective vit D receptor activators (30%), or suitable dialysis parameters. CONCLUSIONS Post-dialysis use of calcimimetic was effective in secondary hyperparathyroidism control, improved gastrointestinal tolerability and ameliorated patients' satisfaction. Based on our findings, post-dialysis use of calcimimetics should be considered in selected patients with low therapeutic compliance.</dc:description>
<dc:type>Journal Article</dc:type>
<dc:language>es</dc:language>
<dc:subject>Calcimiméticos</dc:subject>
<dc:subject>Hemodiálisis</dc:subject>
<dc:subject>Haemodialysis</dc:subject>
<dc:subject>Secondary hyperparathyroidism</dc:subject>
<dc:subject>Calcimimetics</dc:subject>
<dc:subject>Hiperparatiroidismo secundario</dc:subject>
<dc:date>2015 </dc:date>
<dc:title xml:lang="en">Administration of calcimimetics after dialysis: same effectiveness, better gastrointestinal tolerability.</dc:title>
<dc:publisher>Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia</dc:publisher>
</metadata>
</record>
</pubmed-document>
